Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Shire plc | dp45213_8k.htm |
Exhibit 99.1
|
Press Release
|
 |
|
www.shire.com
|
Director/PDMR Share Dealings
March 31, 2014 – Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces that today Ordinary Shares (“Shares”) and American Depository Shares (“ADSs”) of the Company, as set out below, have been acquired for the Non-Executive Directors, being the part of their total fees that are paid in securities for the period of service from January 1 to March 31, 2014.
|
Type of Security (1)
|
Number of Securities
|
||
|
Dominic Blakemore
|
Shares
|
147
|
|
|
William Burns
|
Shares
|
178
|
|
|
Dr. Steven Gillis
|
ADSs
|
57
|
|
|
Dr. David Ginsburg
|
ADSs
|
54
|
|
|
David Kappler
|
Shares
|
186
|
|
|
Susan Kilsby
|
ADSs
|
61
|
|
|
Anne Minto
|
Shares
|
185
|
|
|
David Stout
|
ADSs
|
59
|
|
(1) One ADS is equal to three Shares
The Shares and ADSs were acquired on the London Stock Exchange and NASDAQ respectively at prices of £29.9876 per Share and $147.90 per ADS.
This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.
Tony Guthrie
Deputy Company Secretary
For further information please contact:
|
Investor Relations
|
||
|
Laurie Stelzer
|
lstelzer@shire.com
|
+1 781 482 0733
|
|
Eric Rojas
|
erojas@shire.com
|
+1 781 482 0999
|
|
Sarah Elton-Farr
|
seltonfarr@shire.com
|
+44 1256 894157
|
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas.
www.shire.com
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX